Skip to main content
Figure 3 | Molecular Pain

Figure 3

From: The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy

Figure 3

Effect of AM1710 on chemotherapy-induced mechanical and cold allodynia. AM1710 suppressed both mechanical (A, B) and cold (C, D) allodynia evoked by cisplatin (A, C) or paclitaxel (B, D) treatment. Data are expressed as mean ± SEM (n = 5-13 per group). *** P < 0.001, ** P < 0.01, * P < 0.05 vs. DMSO vehicle, One-way ANOVA followed by Dunnett post hoc test. xxx P < 0.001 vs. AM1710 (1 and 5 mg/kg i.p.), One-way ANOVA followed by Bonferroni post hoc test. + P < 0.05 vs. DMSO vehicle, planned comparison t-test. $$ P < 0.01, $ P < 0.05 vs. pre-drug baseline (−60 min), paired t-test. ### P < 0.001 vs. pre-cisplatin/paclitaxel baseline (BL), repeated measures ANOVA.

Back to article page